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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the efficacy and safety of two different types of fixed-dose dual inhalers (i.e. LABA/LAMA vs ICS/LABA) as well as
combination therapies versus LABA or LAMA monotherapy for patients with moderate to very severe COPD.
B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a globally
prevalent illness, characterised by chronic airway inflammation
leading to slow progression of airflow limitation (GOLD 2017).
The inflammatory nature of the disease leads to variable degrees
of small airway obstruction and destruction of lung parenchyma.
COPD accounts for more than three million deaths annually
and will likely become the third leading cause of death by 2030.
This disease is due primarily to tobacco smoke in industrialised
countries; air pollution and indoor biomass fuel consumption are
the cause in low-income countries. The disease affects men and
women equally (WHO 2016). Despite the worldwide prevalence
of the disease, it remains largely under-recognised and underdiag-
nosed. COPD is a costly disease, with an estimated annual cost of
USD 49.9 billion and an indirect cost estimated at approximately
41% of the total cost in the United States (Patel 2014). Clinically,
the disease is characterised by chronic dyspnoea, productive cough
and exposure to a risk factor. The post-bronchodilator forced expi-
ratory volume in one second (FEV1)/forced vital capacity (FVC)
is required to be less than 0.7 for this diagnosis (GOLD 2017).
The disease course usually is interrupted by episodes of acute exac-
erbation, the frequency of which contributes to overall morbidity
and mortality (Suissa 2012).
Description of the intervention
Management of stable COPD
Once COPD has been diagnosed, the main goals of therapy in-
clude alleviation of symptoms and prevention of disease progres-
sion and acute exacerbations. Smoking cessation is one of themost
important non-pharmacological interventions. Annual influenza
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vaccination is recommended for all patients withCOPD. In obser-
vational studies, influenza vaccination was associated with fewer
outpatient visits, hospitalisations and deaths (Trucchi 2015). Con-
tinuous oxygen therapy (> 15 hours/d) improves mortality among
patients with chronic hypoxaemia and should be prescribed for all
patients with severe resting hypoxaemia (partial pressure of oxy-
gen dissolved in blood (PaO2) ≤ 55 mmHg or peripheral cap-
illary oxygen saturation (SpO2) ≤ 88%) (Qaseem 2011). Pul-
monary rehabilitation has been proven to improve exercise tol-
erance while reducing symptoms and exacerbations (McCarthy
2015; Rochester 2015). Inhaled medications, the mainstay of
pharmacological therapies, are used to improve lung function,
symptoms and quality of life, as well as to reduce acute exacer-
bations. Short-acting bronchodilators are given on an as-needed
basis to provide immediate relief, and long-acting bronchodilators
are used as maintenance therapy in patients with moderate to very
severe disease (Decramer 2012). TheGlobal Initiative for Chronic
Obstructive Lung Disease (GOLD) recommends the addition of a
longer-acting bronchodilator for symptomatic patients with mod-
erate or more severe disease (GOLD 2017).
How the intervention might work
Combination bronchodilators
Fixed-dose dual inhalers include long-acting beta-adrenoceptor
agonist/inhaled corticosteroid (LABA/ICS) and LABA/long-act-
ing muscarinic antagonist (LAMA) combinations. An ICS has
anti-inflammatory effects and may reduce airway inflammation as
well as systemic inflammation, as evidenced by a reduction in C-
reactive protein (Heidari 2012). ICSs and LABAs have synergis-
tic effects when used in combination. Corticosteroids upregulate
beta2-receptors and beta2-agnoists and facilitate translocation of
steroid receptors from the cytoplasm to the nucleus (Falk 2008).
In vitro synergistic effects mentioned above may translate into
clinical benefit. Clinical studies have suggested that a LABA/ICS
combination significantly improved lung function, health status
and rate of exacerbation compared with placebo, LABA alone or
ICS alone (Nannini 2012).
Preclinical studies have suggested drug synergy between a beta2-
adrenoreceptor agonist and amuscarinic agonist. A possible mech-
anism for this synergism is that a muscarinic agonist causes less
suppression of potassium channel opening, leading to relaxation
of the airway smoothmuscle, which further promotes beta2-medi-
ated smoothmuscle relaxationby activating ion channels andother
intracellular signalling pathways (Kume 2014). Clinical studies
have demonstrated that LABA/LAMA combinations were supe-
rior to monotherapies with regard to lung function improvement
and in a recent network meta-analysis (NMA) were associated
with improved quality of life and symptom scores and reduced
COPD exacerbations as compared with LABA or LAMA alone
(Oba 2016a).
Guidelines recommend a LABA/LAMA combination for patients
whose symptoms are not well controlled with a single long-acting
bronchodilator, and a LABA/LAMA or LABA/ICS combination
for those with frequent exacerbations (i.e. two or more exacerba-
tions per year or one hospitalisation per year for an exacerbation).
A LABA/LAMA combination may be preferred to a LABA/ICS
combination, as ICSs are associated with increased risk of pneu-
monia (GOLD 2017; Oba 2016b; Wedzicha 2016).
Why it is important to do this review
Data on the efficacy and safety of fixed-dose LABA/LAMA
combinations are accumulating (Huisman 2015; Oba 2016a;
Schlueter 2016). However, an important clinical question is how
do the efficacy and safety of LABA/LAMA combinations com-
pare with those of LABA/ICS combinations for patients with un-
controlled symptoms and/or frequent exacerbations. Additional
clinical studies including several head-to-head trials comparing
LABA/LAMA and LABA/ICS combinations (Donohue 2015;
Singh 2015; Vogelmeier 2013; Vogelmeier 2015; Wedzicha 2016;
Zhong 2015) have been published since anNMAcomparing com-
bination inhalers focused on studies up toDecember 2013 (Tricco
2015). Our review will update previous systematic reviews on
fixed-dose combination inhalers and long-acting bronchodilators
using the strength of an NMA.
O B J E C T I V E S
To compare the efficacy and safety of two different types of fixed-
dose dual inhalers (i.e. LABA/LAMA vs ICS/LABA) as well as
combination therapies versus LABA or LAMA monotherapy for
patients with moderate to very severe COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) of at least 12
weeks’ duration, published or unpublished. We will not consider
cross-over trials.
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Types of participants
We will include studies that recruited patients aged > 35 years
with a diagnosis of COPD in accordance with American Thoracic
Society-European Respiratory Society (ATS/ERS 2004), GOLD
report (GOLD 2017) or equivalent criteria. Obstructive ventila-
tory defect should be at least moderate, with a baseline FEV1 less
than 80% of predicted. We will exclude studies that enrolled par-
ticipants with a history of asthma or other respiratory disease.
Types of interventions
We will include studies comparing at least two of the following
therapies.
• LAMA monotherapy (aclidinium, glycopyrronium,
tiotropium, umeclidinium).
• LABA monotherapy (indacaterol, formoterol, olodaterol,
salmeterol, vilanterol).
• Fixed-dose combination of LABA/ICS (formoterol/
beclomethasone, formoterol/budesonide, formoterol/ciclesonide,
formoterol/fluticasone, formoterol/mometasone, indacaterol/
mometasone, salmeterol/fluticasone, vilanterol/fluticasone).
• Fixed-dose combination of LABA/LAMA (formoterol/
aclidinium, indacaterol/glycopyrronium, indacaterol/tiotropium,
olodaterol/tiotropium, vilanterol/umeclidinium).
We will allow the use of a short-acting bronchodilator, such as
albuterol (salbutamol), and ipratropium as rescue treatment.
Types of outcome measures
Primary outcomes
• COPD exacerbation (moderate to severe and severe)
Secondary outcomes
• St George’s Respiratory Questionnaire (SGRQ) score and
decrease in SGRQ score ≥ 4 units (responder)
• Transition Dyspnea Index (TDI)
• Mortality
• Total serious adverse events (SAEs)
• Cardiac and COPD SAEs
• Dropout due to adverse event
• Trough FEV1
• Pneumonia
We will use end-of-study data for dichotomous outcomes. For
continuous outcomes, we will use end-of study data and data re-
ported at three, six and 12 months, when available. Moderate ex-
acerbation is defined as worsening of respiratory status that re-
quires treatment with systemic corticosteroids and/or antibiotics;
severe exacerbation is defined as rapid deterioration that requires
hospitalisation.
Search methods for identification of studies
Electronic searches
We will identify studies from the Cochrane Airways Group Spe-
cialised Register (CAGR), which is maintained by the Informa-
tion Specialist for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials,
MEDLINE, Embase, the Cumulative Index to Nursing and Al-
liedHealth Literature (CINAHL), the Allied and Complementary
Medicine Database (AMED) and PsycINFO, and by handsearch-
ing of respiratory journals and meeting abstracts (see Appendix 1
for details).Wewill search all records in theCAGRusing the search
strategy detailed in Appendix 2. We will also conduct a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and theWorld Health
Organization (WHO) trials portal (www.who.int/ictrp/en/). We
will search all databases from their inception to the present, and
we will impose no restriction on language of publication.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references.We will search relevant manufac-
turers’ websites for trial information. We will search for errata or
retractions from included studies published in full text on PubMed
(www.ncbi.nlm.nih.gov/pubmed) and will report within the re-
view the date this was done.
Data collection and analysis
Selection of studies
Two review authors will independently screen studies by title and
abstract to evaluate whether a study meets the inclusion and ex-
clusion criteria. We will select studies that evaluate the clinical
efficacy and safety of any of the following therapies in patients
with COPD: LABA/LAMA, ICS/LABA, LABA and LAMA. We
will resolve disagreements by involving a third review author. We
will record the selection process in sufficient detail to complete a
PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) flow diagram and a ’Characteristics of excluded
studies’ table (Moher 2009).
Data extraction and management
Two review authors will independently extract information on
study design, study size, population, interventions (drug, dose,
inhaler type, allowed comedications), severity of illness and end
points of interest. Wewill gather information if a participant failed
a long-acting bronchodilator before entry into clinical trials. We
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will extract and verify data from each of the existing reviews, which
will be cross-checked and verified by at least two review authors.
We will resolve disagreements regarding values, inconsistencies
and uncertainties by involving a third review author. Two review
authorswill independently extract outcomedata from the included
studies. We will note in the ’Characteristics of included studies’
table if outcome data were not reported in a useable way. We
will resolve disagreements by reaching consensus or by involving a
third review author. One review author will transfer data into the
Review Manager (RevMan 2014) file. We will double-check that
data have been entered correctly by comparing data presented in
the systematic review versus study reports. A second review author
will spot-check study characteristics for accuracy against the trial
report.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve
disagreements by discussion or by consultation with another re-
view author. We will assess risk of bias according to the following
domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We will grade each potential source of bias as high, low or unclear
and will provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes when necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient-reported pain scale). When information on
risk of bias relates to unpublished data or correspondence with a
trialist, we will note this in the ’Risk of bias’ table. When consid-
ering treatment effects, we will take into account the risk of bias
for studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and will report deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
Network meta-analysis
Whenwefind an insufficient number of clinical trials directly com-
paring all relevant treatment options, we can incorporate indirect
comparisons to provide treatment effect estimates by comparing
the relative effects of treatment against a common comparator, or
by combining a variety of comparisons (variously referred to as
mixed or multiple treatment comparisons, or NMAs) (Lu 2004).
We will conduct NMAs using a Bayesian Markov chain Monte
Carlo method and will use WinBUGS 1.4.3. for primary anal-
yses. We will consider trials within separate analytical networks
on the basis of risks of COPD complications. We will consider as
high risk all trials that recruited patients with at least one COPD
exacerbation in the 12 months before study entry. We will con-
sider as low risk all trials that do not meet the above criteria. We
will compare each pair of treatments by estimating an odds ratio
(OR) or hazard ratio (HR) for dichotomous outcomes, and a dif-
ference in mean or median for continuous outcomes. We will use
a normal likelihood with identity link for continuous outcomes
(FEV1, TDI and SGRQ) and a binomial likelihood with cloglog
link for mortality, SAEs (total, cardiac and COPD), dropouts due
to adverse events, SGRQ responders and pneumonia to allow for
different study durations because a longer follow-up would likely
make a difference in study results for these outcomes. We will use a
shared parameter model for exacerbation outcomes, whereby data
on the log hazard ratio (lnHR) are modelled with the assumption
that continuous treatment differences (lnHR and standard error)
have a normal likelihood. When lnHR data are not available, or
when appropriate covariance matrices cannot be extracted for tri-
als with more than two arms, we will model data on the number
of participants with at least one exacerbation out of the total num-
ber of participants at a given time as lnHR by using a binomial
likelihood with cloglog link. We will use HR data in preference
to dichotomous data when available and will consider only HR
for the first event. We will assess model fit by comparing residual
deviance versus the number of data points, and by assessing the
size of the between-study standard deviation (SD).
Direct pairwise meta-analysis
We will conduct pairwise meta-analyses considering only direct
evidence. We will analyse dichotomous data as ORs and contin-
uous data as mean differences or standardised mean differences
(SMDs), along with their 95% confidence intervals (CIs). We will
enter data presented as a scale with a consistent direction of effect.
We will use a random-effects model as a primary analysis for all
outcomes and a fixed-effect model as a sensitivity analysis. We will
applyHaldane correction by adding 0.5 to each count when a data
set contains zero in any cell, to make a calculation possible for the
main effect of variance (Bhaumik 2012). We will undertake meta-
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analyses only when this is meaningful (i.e. if treatments, partici-
pants and the underlying clinical question are similar enough for
pooling to make sense). When multiple trial arms are reported in
a single trial, we will include only the relevant arms.
Unit of analysis issues
We will analyse dichotomous data by using number of partici-
pants (rather than events) as the unit of analysis to avoid multiple
counting of data from the same participant.
Dealing with missing data
We will request additional data from manufacturers through clin-
icalstudydatarequest.com and/or from the responsible author of
the included study to verify key study characteristics and to obtain
missing numerical outcome data when possible (e.g. when a study
is identified as an abstract only). When this is not possible, and
when the missing data are thought to introduce serious bias, we
will explore the impact of including such studies in the overall
assessment of results by performing a sensitivity analysis.
Assessment of heterogeneity
Assessment of similarity of participants, interventions and
trial methods
We will assess similarity of participants, interventions, potential
effect modifiers and trial methods in all studies and across pairwise
comparisons to ensure low heterogeneity and consistency in the
NMA. We will formulate a table to assess similarity of participant
characteristics in class pairwise comparisons (e.g. LABA/LAMA vs
LABA/ICS, LABA/LAMA vs LABA.). The initial editorial review
had questioned the similarity of patient populations across clini-
cal trials owing to the presence of potential effect modifiers. After
a preliminary search of clinical studies and review of inclusion/
exclusion criteria, participant characteristics and trial methods,
we decided to divide the study populations into those with and
those without a history of COPD exacerbations, which we viewed
as a potential effect modifier. This is consistent with the GOLD
2017 update (GOLD 2017), which recommends treatment op-
tions based on exacerbation history. Otherwise, the distribution
of participant and study characteristics appeared sufficiently sim-
ilar in different sets of RCTs that go into an indirect comparison.
We will consider confounding by difference in the distribution
of effect modifiers when carrying out subgroup comparisons be-
tween trials. If effect modifiers are clearly different (treatment-by-
covariate interactions) between clinical trials with a formal analy-
sis, we will emphasise results derived by direct comparison and will
downgrade NMA estimates as providing a lower level of evidence
or as probably biased.
Assessment of heterogeneity and statistical consistency
We will assess heterogeneity by comparing a between-trials SD
versus the size of relative treatment effects, using log-scale for OR
and HR. We will assess consistency by comparing the model fit
and between-study heterogeneity from NMAmodels versus those
from an unrelated effects (inconsistency) model (Dias 2013a; Dias
2013b). We will use this test to determine the presence and area
of inconsistency. We will qualitatively compare the results from
direct pairwise meta-analysis versus NMA estimates to check for
broad agreement. If we identify substantial inconsistency, we will
explore factors, including participant and design characteristics,
that may contribute to inconsistency. We will comment on these
characteristics and will restrict our analysis to a subset of studies
for which the evidence may be more comparable. For the pairwise
meta-analysis, we will test heterogeneity among studies with I² >
30% indicating substantial heterogeneity (Higgins 2003).We will
use optimal information size calculations as an objective measure
of imprecision for grading evidence, with an α of 0.05 and a β of
0.80 (Guyatt 2011a).Wewill address heterogeneity through direct
comparison based on Grading of Recommendations Assessment,
Development and Evaluation (GRADE) criteria (Guyatt 2011b).
Assessment of reporting biases
We will minimise reporting bias from unpublished studies or se-
lective outcome reporting by using a broad search strategy and
by checking references of included studies and relevant systematic
reviews. For each outcome, we will estimate and present the pro-
portion of studies contributing data to the NMA. For the pair-
wise meta-analysis, we will assess small study and publication bias
through visual inspection of a funnel plot and performance of the
Egger test (Egger 1997) if more than 10 studies are being pooled.
We will assume the presence of small study bias when the number
of participants is fewer than 50 per study, 1000 per pooled anal-
ysis or 100 per arm when no more than 10 studies can be pooled
(Dechartres 2013; Nüesch 2010). We will assume a selective re-
porting bias if a clinical trial is not registered (Mathieu 2009).
Data synthesis
We will consider all regimen doses as individual treatments. If the
network structure allows, we will consider a class-model meta-
analysis as the primary analysis (as used in Kew 2014). We will
estimate the probability that each class ranks at one of the four
possible positions. For NMAs, we will compare fixed-effect and
random-effects models using the Deviance Information Criterion
(DIC).Wewill use themodel with lower values on theDIC.When
two models have a similar DIC (i.e. within 3 units of each other),
we will choose a model on the basis of heterogeneity in the pair-
wise comparison. We will use a random-effects model if we detect
heterogeneity and a fixed-effect model otherwise (Spiegelhalter
2002).We will report all results for theNMA as posterior medians
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or means with corresponding 95% credible intervals. For pairwise
meta-analyses, we will use a random-effects model, and for sensi-
tivity analysis, we will use a fixed-effect model.
Summary of findings table
Wewill use the GRADE system to assess the quality of evidence as
it relates to studies that contribute data to the pairwise meta-anal-
yses. We will create a ’Summary of findings’ table using the follow-
ing outcomes:mortality, COPDexacerbations (moderate to severe
and severe), pneumonia, SGRQ responder, TDI and change from
baseline in SGRQ. We will use the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the quality of a body of evidence as
it relates to studies that contribute data to meta-analyses for pre-
specified outcomes. We will use methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) and will
use GRADEpro GDT 2016 software. We will justify all decisions
to downgrade or upgrade the quality of studies by using footnotes,
and we will make comments to aid the reader’s understanding of
the review when necessary.
Subgroup analysis and investigation of heterogeneity
We plan to perform subgroup analyses based on baseline disease
severity, treatment duration, smoking status, type of each arm
(intraclass comparison), dose of ICS component for pneumonia
and publication status, provided that treatments could be com-
pared indirectly with those in other trial comparisons through one
or more common comparators (i.e. the networks remained ’con-
nected’). If we detect substantial heterogeneity in the NMA, we
will explore potential sources of heterogeneity by fitting covari-
ates (i.e. FEV1 at baseline, treatment duration, publication status
(published vs unpublished and publication year), smoking status,
comorbidity, etc.) in a meta-regression analysis and conducting
a subgroup analysis based on inhaler strength (analyse all doses
separately). We will use the formal test for subgroup interactions
provided in Review Manager (RevMan 2014).
Sensitivity analysis
Wewill perform sensitivity analyses while excluding studies at high
risk of bias from the overall analysis (provided that the networks
remain connected) and will analyse studies of different duration
separately. We will use a model not used in the primary analysis
(fixed-effect or random-effects) as a sensitivity analysis for both
NMAs and pairwise meta-analyses. For the NMA, we will explore
bias adjustment methods based on risk of bias of each study for
blinding and allocation concealment components, on their own
or in combination (subject to network structure) (Dias 2010).
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
COPD search
1. Lung Diseases, Obstructive/
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2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD OR AECOPD):TI,AB,KW
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 mometasone* AND formoterol*
#8 fluticasone* AND salmeterol*
#9 budesonide* AND formoterol*
#10 beclomethasone* AND formoterol*
#11 fluticasone* AND formoterol*
#12 Flutiform or Fostair or Simplyone
#13 fluticasone* AND vilanterol*
#14 mometasone* AND indacaterol*
#15 formoterol* and ciclesonide*
#16 QMF149
#17 GW685698 AND GW642444
#18 steroid* OR corticosteroid* or ICS
#19 (long-acting* or long NEXT acting*) NEAR beta*
#20 #18 AND #19
#21 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #20
#21 formoterol* AND aclidinium*
#22 indacaterol* AND glycopyrronium*
#23 indacaterol* AND tiotropium*
#24 olodaterol* AND tiotropium*
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#25 vilanterol* AND umeclidinium*
#26 QVA149
#27 Ultibro or Stiolto or Duaklir Genuair
#28 Muscarinic* Next Antagonist*
#29 #19 AND #28
#30 #21 or # 22 or #23 or #24 or #25 or #26 or #27 or # 29
#31 combin* NEAR inhaler*
#32 FDC:ti,ab
#33 #21 or #30 or #31 or #32
#34 #6 AND #33
[In search line #4, MISC1 denotes the field in which the reference has been coded for condition, in this case, COPD]
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